Back to today’s briefing

Story perspectives

FDA Reviews Mifepristone Safety Amid Coercion Concerns

7/26/2025

50 6

Summary

Story summary

FDA Commissioner Marty Makary announced a review of safety data on the abortion drug mifepristone, addressing rising concerns about potential coercion and its impact on women. While he advocates for open-mindedness, he has no immediate plans to alter existing policies. A recent investigation uncovered alarming access to mifepristone without necessary doctor consultations, intensifying safety worries.

1 of 1

Story summary

FDA Commissioner Marty Makary announced a review of safety data on the abortion drug mifepristone, addressing rising concerns about potential coercion and its impact on women. While he advocates for open-mindedness, he has no immediate plans to alter existing policies. A recent investigation uncovered alarming access to mifepristone without necessary doctor consultations, intensifying safety worries.